Genomic Health, Inc. has announced they have had positive results from a large clinical validation study of a biopsy-based prostate cancer test designed to predict adverse pathology in men with early prostate cancer.
The study, performed in collaboration with prostate cancer researchers at the University of California, San Francisco (UCSF), met its primary endpoint by demonstrating that the multi-gene Oncotype DX® Genomic Prostate Score (GPS), assessed in prostate needle biopsy tumor tissue, could predict adverse pathology for men with early-stage prostate cancer. They are planning on submitting their complete data in a presentation at the 2013 ASCO Genitourinary Cancers Symposium in February.
Based on these results, Genomic Health is completing the necessary work in its Clin